Результати пошуку - Ida Enquist

  • Показ 1 - 10 результатів із 10
Уточнити результати
  1. 1
    No evidence for activation of the unfolded protein response in neuronopathic models of Gaucher disease

    No evidence for activation of the unfolded protein response in neuronopathic models of Gaucher disease за авторством Tamar Farfel‐Becker, Einat B. Vitner, H. Dekel, Noa Leshem, Ida Enquist, Stefan Karlsson, Anthony H. Futerman

    Опубліковано 2009
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  2. 2
    Effective cell and gene therapy in a murine model of Gaucher disease

    Effective cell and gene therapy in a murine model of Gaucher disease за авторством Ida Enquist, Eva Nilsson, Andreas Ooka, Jan‐Eric Månsson, Karin Olsson, Mats Ehinger, Roscoe O. Brady, Johan Richter, Stefán Karlsson

    Опубліковано 2006
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  3. 3
    Lymph node-independent liver metastasis in a model of metastatic colorectal cancer

    Lymph node-independent liver metastasis in a model of metastatic colorectal cancer за авторством Ida Enquist, Zinaida Good, Adrian M. Jubb, Germaine Fuh, Xi Wang, Melissa R. Junttila, Erica L. Jackson, Kevin G. Leong

    Опубліковано 2014
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  4. 4
    Murine models of acute neuronopathic Gaucher disease

    Murine models of acute neuronopathic Gaucher disease за авторством Ida Enquist, Christophe Lo Bianco, Andreas Ooka, Eva Nilsson, Jan‐Eric Månsson, Mats Ehinger, Johan Richter, Roscoe O. Brady, Deniz Kirik, Stefan Karlsson

    Опубліковано 2007
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  5. 5
    FP13.03 IMpower110: Updated OS Analysis of Atezolizumab vs Platinum-Based Chemotherapy as First-Line Treatment in PD-L1–Selected NSCLC

    FP13.03 IMpower110: Updated OS Analysis of Atezolizumab vs Platinum-Based Chemotherapy as First-Line Treatment in PD-L1–Selected NSCLC за авторством Roy S. Herbst, Filippo de Marinis, Giuseppe Giaccone, A. Vergnenègre, Carlos H. Barrios, Masahiro Morise, Enriqueta Felip, Cristina Oprean, Y. Kim, Zoran Andrić, Simonetta Mocci, Ida Enquist, K.M. Komatsubara, Mark L. McCleland, Yu Deng, Hiroshi Kuriki, Matthias Villalobos, S. Phan, David R. Spigel, Jacek Jassem

    Опубліковано 2021
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  6. 6
    Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC

    Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC за авторством Jacek Jassem, Filippo de Marinis, Giuseppe Giaccone, A. Vergnenègre, Carlos H. Barrios, Masahiro Morise, Enriqueta Felip, Cristina Oprean, Young‐Chul Kim, Zoran Andrić, Simonetta Mocci, Ida Enquist, Kimberly M. Komatsubara, Mark L. McCleland, Hiroshi Kuriki, Monette Villalobos, See Phan, David R. Spigel, Roy S. Herbst

    Опубліковано 2021
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  7. 7
    IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC

    IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–se... за авторством David R. Spigel, Filippo de Marinis, Giuseppe Giaccone, Niels Reinmuth, A. Vergnenègre, C.H. Barrios, Masahiro Morise, Enriqueta Felip, Zoran Andrić, Sarayut Lucien Geater, Mustafa Özgüroğlu, Simonetta Mocci, Mark L. McCleland, Ida Enquist, K.M. Komatsubara, Yu Deng, Hiroshi Kuriki, Xiaohui Wen, Jacek Jassem, Roy S. Herbst

    Опубліковано 2019
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  8. 8
    LBA1 Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study

    LBA1 Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB):... за авторством Roy S. Herbst, Filippo de Marinis, Giuseppe Giaccone, Niels Reinmuth, A. Vergnenègre, Carlos H. Barrios, Masahiro Morise, Enriqueta Felip, Zoran Andrić, Sarayut Lucien Geater, Mustafa Özgüroğlu, Simonetta Mocci, Mark L. McCleland, Wenbo Zou, Ida Enquist, K.M. Komatsubara, Yu Deng, Hiroshi Kuriki, David R. Spigel, Jacek Jassem

    Опубліковано 2019
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  9. 9
    O81 IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (ATEZO) monotherapy vs platinum-based chemotherapy (CHEMO) as first-line (1L) treatment in PD-L1–selected NSCLC

    O81 IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (ATEZO) monotherapy vs platinum-based chemotherapy (CHEMO) as first-line (1L) treatment... за авторством Roy S. Herbst, Filippo de Marinis, Giuseppe Giaccone, Niels Reinmuth, A. Vergnenègre, Carlos H. Barrios, Masahiro Morise, E. Felip Font, Zoran Andrić, Sarayut Lucien Geater, Mustafa Özgüroğlu, Simonetta Mocci, Mark L. McCleland, Ida Enquist, K.M. Komatsubara, Yu Deng, Hiroshi Kuriki, Xiaohui Wen, Jacek Jassem, David R. Spigel

    Опубліковано 2020
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  10. 10
    Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

    Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC за авторством Roy S. Herbst, Giuseppe Giaccone, Filippo de Marinis, Niels Reinmuth, A. Vergnenègre, Carlos H. Barrios, Masahiro Morise, Enriqueta Felip, Zoran Andrić, Sarayut Lucien Geater, Mustafa Özgüroğlu, Wei Zou, Alan Sandler, Ida Enquist, Kimberly M. Komatsubara, Yu Deng, Hiroshi Kuriki, Xiaohui Wen, Mark L. McCleland, Simonetta Mocci, Jacek Jassem, David R. Spigel

    Опубліковано 2020
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:

Інструменти для пошуку: